Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to ...

“This is particularly relevant for neoadjuvant settings in specific sarcoma subtypes such as angiosarcoma and fibrosarcoma.” OH2 is a genetically engineered oncolytic virus derived from the wild-type ...